DNA
NYSEGinkgo Bioworks Holdings Inc.
Price$8.24+1.40 (+20.45%)
2026-03-052026-06-08
News · 26 weeks37-78%
2025-12-142026-06-07
Mix2190d
- Insider9(43%)
- SEC Filings6(29%)
- Other4(19%)
- Earnings2(10%)
Latest news
25 items- INSIDEROfficer Coen Steven P. converted options into 743 shares and sold $2,559 worth of shares (307 units at $8.33), increasing direct ownership by 0.87% to 50,704 units (SEC Form 4) (tax liability)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- PRGinkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug DiscoveryNew co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identificationBOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.SCHEDULE 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
- PRThe $59B Quiet Shift Reshaping How Patients Access CareIssued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and
- SECSEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- PRGinkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous LabGinkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity businessBOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. First Quarter 2026 Financial ResultsAs previously announced, Ginkgo completed the divestiture
- PRGinkgo Bioworks Announces Date of First Quarter 2026 Results PresentationPresentation and Q&A session scheduled for post-market on Thursday, May 7, 2026BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a question ahead of the presen
- SECSEC Form DEFA14A filed by Ginkgo Bioworks Holdings Inc.DEFA14A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECSEC Form DEF 14A filed by Ginkgo Bioworks Holdings Inc.DEF 14A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- INSIDERSEC Form 4 filed by Coen Steven P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Coen Steven P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Canton Barry4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Shetty Reshma P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Shetty Reshma P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Canton Barry4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Kelly Jason R4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.SCHEDULE 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
- INSIDERSEC Form 4 filed by Ginkgo Bioworks Holdings Inc.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- SECSEC Form 144 filed by Ginkgo Bioworks Holdings Inc.144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
- PRGinkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab InfrastructureBOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser. Ginkgo Cloud Lab runs on the company's proprietary Reconfigurable Automation Carts (RACs). These modular units combine high-precision robotic arms, maglev sample transport tracks, and industrial-grade software to create an endlessly flexible laboratory environment.The Cloud Lab provides remote access to a fleet of over
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECSEC Form S-8 filed by Ginkgo Bioworks Holdings Inc.S-8 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECSEC Form 10-K filed by Ginkgo Bioworks Holdings Inc.10-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
DNA FAQ
7 questionsWhat does Ginkgo Bioworks Holdings Inc. do?
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.Where does DNA stock trade?
Ginkgo Bioworks Holdings Inc. (DNA) is listed on NYSE.What sector and industry is DNA in?
Ginkgo Bioworks Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Ginkgo Bioworks Holdings Inc. go public?
Ginkgo Bioworks Holdings Inc. (DNA) completed its IPO in 2021.What are analysts saying about DNA?
Ginkgo Bioworks Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Sell on 2024-05-15. Recent price targets range from $125.00 to $600.00.What companies are similar to DNA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare DNA side-by-side with any of them on Quantisnow.How can I track DNA on Quantisnow?
Quantisnow aggregates Ginkgo Bioworks Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DNA to receive live email and push alerts on every new disclosure.